3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Leukemia, Myeloid, Acute
21
Precursor Cell Lymphoblastic Leukemia-Lymphoma
20
Myelodysplastic Syndromes
19
Lymphoma, Non-Hodgkin
17
Leukemia, Lymphocytic, Chronic, B-Cell
15
Hodgkin Disease
15
Graft vs Host Disease
13
Lymphoma, Mantle-Cell
12
Leukemia
12
Multiple Myeloma
11
Lymphoma, Large B-Cell, Diffuse
11
Sarcoma
10
Lymphoma
10
Lymphoma, Follicular
9
Lymphoma, B-Cell, Marginal Zone
9
Burkitt Lymphoma
9
Myeloproliferative Disorders
8
Waldenstrom Macroglobulinemia
7
Tuberous Sclerosis
7
Neoplasms
7
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
7
Hematologic Neoplasms
7
Congenital Abnormalities
7
Primary Myelofibrosis
6
Lymphoma, Large-Cell, Immunoblastic
6
Leukemia, Myelomonocytic, Chronic
6
Leukemia, Myeloid, Chronic-Phase
6
Leukemia, Myeloid, Accelerated Phase
6
Breast Neoplasms
6
Osteosarcoma
5
Interventions
Mitomycin
2
Capecitabine
2
Tacrolimus
1
Specimen Handling
1
Sirolimus
1
Nivolumab
1
Magnetic Resonance Spectroscopy
1
Lansoprazole
1
Ipilimumab
1
Hyperthermic Intraperitoneal Chemotherapy
1
Cytoreduction Surgical Procedures
1
Clarithromycin
1
CTLA-4 Antigen
1
Bromelains
1
Amoxicillin
1
Alemtuzumab
1
Acetylcysteine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Pseudomyxoma Peritonei
×
Sirolimus
×
Clear all
NCT06084780
2026-06-05
TRANSCAPE
Case Comprehensive Cancer Center
Phase 2
Not yet recruiting
20 enrolled